Product Pipeline
Lorus has product candidates in three classes of anticancer therapies:
RNA-Targeted Therapies-
Small Molecule Platform 
Immunotherapy
Clinical Development Focus
| Drug Candidate (Indication) | Target | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
Oncology Preclinical Drug Candidates
| Drug Candidate | Target | Discovery | Lead Ident. | Preclinical | Phase 1 |
|---|---|---|---|---|---|
Immune-modulation |
|||||
Lorus believes that a range of therapeutic options is important for successful cancer treatment. Lorus’ research and development program focuses on several distinct technologies with one common objective: to develop drugs that contribute to an improved quality of life for cancer patients, and which are well tolerated by patients, and can be used alone or in combination with other leading approved therapies to enhance their effectiveness.